p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression

Attenuating Regulatory T Cell Induction by TLR Agonists through Inhibition of p38 MAPK Signaling in Dendritic Cells Enhances Their Efficacy as Vaccine Adjuvants and Cancer Immunotherapeutics

(2014) A. G. Jarnicki et al.   JOURNAL OF IMMUNOLOGY

CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy

(2013) Caspar Kühnöl et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

SnapShot: p38 MAPK Signaling

(2013) Natalia Trempolec et al.   CELL

The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy

(2013) Amy E Moran et al.   CURRENT OPINION IN IMMUNOLOGY

Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies

(2013) Pawel Kalinski et al.   Expert Review of Vaccines

Novel function for the p38-MK2 signaling pathway in circulating CD1c+ (BDCA-1+) myeloid dendritic cells from healthy donors and advanced cancer patients; inhibition of p38 enhances IL-12 whilst suppressing IL-10

(2013) Hester A. Franks et al.   INTERNATIONAL JOURNAL OF CANCER

Current Status and Future Perspectives of Dendritic Cell-Based Cancer Immunotherapy

(2013) D. H. Yi et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction

(2012) J. He et al.   CANCER RESEARCH

Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity

(2012) S. Hong et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition

(2012) Dinja Oosterhoff et al.   OncoImmunology

Regulation of dectin-1-mediated dendritic cell activation by peroxisome proliferator-activated receptor-gamma ligand troglitazone

(2011) G. Kock et al.   BLOOD

Targeting Regulatory T Cells in Cancer

(2011) W. L. Byrne et al.   CANCER RESEARCH

Control of Immunity by the TNFR-Related Molecule OX40 (CD134)

(2010) Michael Croft   Annual Review of Immunology

Positive and Negative Transcriptional Regulation of the Foxp3 Gene is Mediated by Access and Binding of the Smad3 Protein to Enhancer I

(2010) Lili Xu et al.   IMMUNITY

The Regulation of Th1 Responses by the p38 MAPK

(2010) Z. Yang et al.   JOURNAL OF IMMUNOLOGY

Signaling Through OX40 Enhances Antitumor Immunity

(2010) Shawn M. Jensen et al.   SEMINARS IN ONCOLOGY

Differences in Tumor Regulatory T-Cell Localization and Activation Status Impact Patient Outcome

(2009) C. Menetrier-Caux et al.   CANCER RESEARCH

Activation of p38 Mitogen-Activated Protein Kinase Drives Dendritic Cells to Become Tolerogenic in Ret Transgenic Mice Spontaneously Developing Melanoma

(2009) F. Zhao et al.   CLINICAL CANCER RESEARCH

Cochlear protection from acoustic injury by inhibitors of p38 mitogen-activated protein kinase and sequestosome 1 stress protein

(2009) K. Tabuchi et al.   NEUROSCIENCE

Expression of Costimulatory Ligand CD70 on Steady-State Dendritic Cells Breaks CD8+ T Cell Tolerance and Permits Effective Immunity

(2008) Anna M. Keller et al.   IMMUNITY

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

(2008) Silvia Piconese et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A20 is an antigen presentation attenuator and its inhibition overcomes regulatory T cell–mediated suppression

(2008) Xiao-Tong Song et al.   NATURE MEDICINE